CARsgen Therapeutics Holdings Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 2171.HK | LEGN | LYEL | 2616.HK | 2126.HK | 688382.SS | |
|---|---|---|---|---|---|---|
| Market cap | 6.48B | 4.43B | 378.11M | 8.98B | 1.11B | 8.38B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 96.2 | 21.7 | -2.4 | 137.0 | -3.0 | -43.8 |
| Price/book | 5.0 | 3.6 | 1.3 | 5.9 | 2.0 | 6.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −29.85% | −29.66% | −13.70% | −7.84% | −31.72% | −48.70% |
| Today | +3.36% | +6.01% | +43.27% | +4.16% | +7.91% | +4.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 2171.HK news ›Carsgen Therapeutics Holdings Limited Completes First Patient Dose of Ct1190b in China Phase I Registrational Trial
CARsgen Therapeutics Holdings Limited announced that CT1190B, an allogeneic CAR T-cell product targeting CD19/CD20, has completed first patient dose in its registrational Phase I clinical trial in... CARsgen Therapeutics Holdings Limited…
Tranche Update on CARsgen Therapeutics Holdings Limited's Equity Buyback Plan announced on October 21, 2025.
From January 1, 2026 to May 22, 2026, the company has repurchased 0 shares, representing 0% for HKD 0 million. With this, the company has completed the repurchase of 8,273,000 shares, representing... Published on 09/14/2026 at 10:00 pm EDT…
CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy
CARsgen Therapeutics said its investigational new drug application for CT1190B, an allogeneic CAR T-cell therapy targeting CD19/CD20, received clearance from China's National Medical Products... CARsgen Therapeutics Holdings Limited…
CARsgen Therapeutics Doses First Patient in CT1190B Lymphoma Trial
CARsgen Therapeutics dosed the first patient in a registrational Phase 1 clinical trial of CT1190B in China, according to a filing with the Hong Kong Stock Exchange on Tuesday. The trial is... CARsgen Therapeutics Holdings Limited…
CARsgen Therapeutics Gets Nod for Gastric Cancer Drug Application in China
CARsgen Therapeutics obtained approval for the new drug application of satricabtagene autoleucel from China's National Medical Products Administration, according to a Monday Hong Kong bourse... CARsgen Therapeutics Holdings Limited…
CARsgen Therapeutics Holdings Limited: Relative Strength Chart - Stock Hong Kong S.E.
Compare CARsgen Therapeutics Holdings Limited with the company of your choice via a Relative Strength chart. Real-time 2171 price, Hong Kong S.E. stock exchange Relative Strength Chart CARsgen Therapeutics Holdings Limited Biotechnology &…
Carsgen Therapeutics Holdings Limited Receives Approval for Satri-Cel, the World's First Car T-Cell Therapy Product for Solid Tumors
CARsgen Therapeutics Holdings Limited announced that as informed by the National Medical Products Administration, the New Drug Application of satricabtagene autoleucel , the proprietary autologous... CARsgen Therapeutics Holdings Limited…
CARsgen Therapeutics Holdings Limited Announces CT0596 Receives IND Clearance from NMPA for Treatment of Relapsed/Refractory Multiple Myeloma
CARsgen Therapeutics Holdings Limited announced that CT0596, an allogeneic CAR T-cell product targeting BCMA, has achieved Investigational New Drug clearance from the National Medical Products... CARsgen Therapeutics Holdings Limited…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com5
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.